James R. Kasinger - 10 Mar 2024 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
General Counsel and Secretary
Signature
/s/ AJ Silver, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
10 Mar 2024
Net transactions value
-$304,514
Form type
4
Filing time
12 Mar 2024, 17:45:09 UTC
Previous filing
21 Feb 2024
Next filing
22 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +5,500 +9.6% 62,871 10 Mar 2024 Direct F1
transaction CRSP Common Shares Sale $219,206 -2,801 -4.5% $78.26 60,070 11 Mar 2024 Direct F2
transaction CRSP Common Shares Options Exercise +2,250 +3.7% 62,320 11 Mar 2024 Direct F1
transaction CRSP Common Shares Sale $85,308 -1,146 -1.8% $74.44 61,174 12 Mar 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Options Exercise -5,500 -25% 16,500 10 Mar 2024 Common Shares 5,500 Direct F1, F3
transaction CRSP Restricted Stock Units Options Exercise -2,250 -50% 2,250 11 Mar 2024 Common Shares 2,250 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3 This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.
F4 This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.